Earnings Routine −

Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results

Kane Biotech Revenue Plummets as Restructuring Costs Mount; Cash Runway Tightens

By The Northwire Desk — AI Analysis Apr 23, 2026 · 18:00 KNE · 0.035 Kane Biotech Inc.

Executive Summary

Kane Biotech Inc. released Fourth Quarter and Full Year 2025 financial results on April 23, 2026.
Total revenue for FY 2025 was $427,869, a significant decrease from $2,080,879 in FY 2024 (-79%).
Gross profit turned negative at $(640) compared to $872,096 positive gross profit in FY 2024.
Operating expenses were reduced by approximately 45% to $2,653,208 from $4,795,093 due to restructuring and workforce reductions.
Net loss narrowed slightly to $(2,721,239) compared to $(3,161,097) in FY 2024.
Cash position as of December 31, 2025, was $901,698.
Regulatory milestones include FDA 510(k) clearance for revyve Antimicrobial Skin and Wound Cleanser (Q1 2026) and Health Canada approval for the Gel Spray (Dec 2025).
Strategic partnerships established with Marathon Medical Corporation to access U.S. federal procurement channels (VA, DOD, IHS).
Recent financing includes multiple private placements in 2025/2026 totaling over $4.6 million gross proceeds, heavily reliant on insider participation ($1M cash advance received April 2026).

Material Impact

The financial results confirm the severe revenue contraction anticipated following Q3 2025 earnings (where revenue dropped to $8k from $1.2M), making this news largely expected rather than a surprise shock.
While operating expenses were cut, they remain disproportionately high relative to the minimal revenue generated ($2.65M OpEx vs $427k Revenue).
The negative gross profit indicates current commercial operations are not covering direct costs of goods sold, highlighting execution risks in scaling sales.
Cash position of ~$900k against a run rate of ~$220k/month (based on FY 2025 OpEx) suggests a runway of approximately 4 months without additional capital raises.
The reliance on insider financing ($1M advance, multiple private placements with insiders) signals management confidence but introduces dilution and related-party transaction risks.
Given the prior disclosure of revenue collapse in Q3 2025 and restructuring plans, this update is categorized as Routine - Negative; it validates negative fundamentals without introducing new unexpected material shocks to the stock price trajectory.

KNE · Price

Company Overview

Company: Kane Biotech Inc., a biotechnology company focused on antimicrobial wound care solutions.
Flagship Product: revyve® Antimicrobial Wound Gel, Spray, and Cleanser.
Technology: Thermoreversible gel technology that normalizes chronic wound pH to accelerate healing and eradicate biofilms (S. aureus, P. aeruginosa).
Regulatory Status: FDA 510(k) cleared for Gel, Spray, and Cleanser; Health Canada approved for Gel and Spray.
Strategy: Pivot from animal health manufacturing to commercial wound care in North America via multi-channel distribution (federal procurement + private distributors).

More from Kane Biotech Inc.